Global Orally Inhaled Corticosteroids Market Report 2015-2022
DUBLIN, Apr. 09, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/qkmh9t/_orally_inhaled) has announced the addition of the " Orally Inhaled Corticosteroids to 2022 " report to their offering.
Asthma continues to be a health segment that presents challenges to the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they reduce inflammation and swelling in the airways, orally inhaled corticosteroids are an indispensable tool for the treatment of asthma. The market entry of combination drug inhalers that deliver a corticosteroid and a bronchodilator from the same inhaler are providing important options for both clinicians and patients.
Key Topics Covered:
1.Executive Summary
2. Orally Inhaled Corticosteroid Market Overview
3.The Asthma Therapeutics Marketspace
- Competing Drug Treatments
- Corticosteroids and Asthma
- Demand Drivers
- Technology Factors
- Competitive Landscape
4. Asthma Market Risks and Opportunities
5.Global Patient Demographics
- Regional Market Drivers
- Pediatric Asthma -the Growing Therapeutic Need
6. Inhaler Technologies for Delivering Corticosteroids
7. Dry Powder Inhalers
- DPI Formulation Technology
- Characteristics and Parameters
- DPI Excipients and Packaging
- Metered Dose Inhalers
- MDI Device Selection Criteria
- Ease-of-Use Factors
- Nebulizers
8. Inhaled Corticosteroids - Product Analysis, Market Data & Forecasts
9. Beclomethasone, QVAR 40/80 (MDI)
- Budesonide, Pulmicort (DPI)
- Budesonide, Pulmicort (Nebulizer)
- Generic Budesonide (Nebulizer)
- Budesonide/Formoterol (Symbicort) Combination Drug Inhaler (MDI)
- Ciclesonide, Alvesco (MDI)
- Ciclesonide, Zetonna (MDI)
- Flunisolide, Aerospan HFA (MDI)
- Fluticasone, Arnuity Ellipta (DPI)
- Fluticasone, Flovent HFA (MDI)
- Fluticasone, Flovent Diskus50/100/250 (DPI)
- Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
- Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
- Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI)
- Mometasone, Asmanex HFA (MDI)
- Mometasone, Asmanex Twisthaler (DPI)
- Umeclidinium, Incruse Ellipta (DPI)
- Umeclidinium/Vilanterol (Anora Ellipta) Combination Drug Inhaler (DPI)
10. Market Factors
11. Regulatory Issues
- Patient Compliance
- Prescribing Trends
- Healthcare Economics
- Regional Market Factors
- Connected Devices
12. Market Sector Company Profiles
For more information visit http://www.researchandmarkets.com/research/qkmh9t/_orally_inhaled
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article